Chardan Cuts Alnylam Price Target to $375 From $425, Keeps Buy
Chardan lowered its price target on Alnylam Pharmaceuticals to $375 from $425 and maintained a Buy rating.
Chardan lowered its price target on Alnylam Pharmaceuticals to $375 from $425 and maintained a Buy rating.